Australia markets open in 7 hours 36 minutes

Kezar Life Sciences, Inc. (2KZ.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.7700+0.0700 (+10.00%)
As of 08:02AM CEST. Market open.
Full screen
Previous close0.7000
Open0.7700
Bid0.7500 x 0
Ask0.7800 x 0
Day's range0.7700 - 0.7700
52-week range0.6150 - 2.8000
Volume221
Avg. volume2,034
Market cap62.476M
Beta (5Y monthly)0.46
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., May 06, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar’s c

  • Business Wire

    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2

  • Business Wire

    Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.